Media ReleasesImugene Limited

View All Imugene Limited News

Imugene Announces Clinical Cancer Research Journal Publishes B-Vaxx Phase 1 Data

Sydney, Australia, 26 February 2019: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company is pleased to announce that the Phase 1 clinical trial data for its B cell peptide cancer vaccine B-Vaxx has been published in the prestigious American Association for Cancer Research journal Clinical Cancer Research.

The title of the article is "Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors," and is primarily authored by Imugene’s SAB members Professor Pravin Kaumaya from the Ohio State University and Dr Tanios Bekaii-Saab from the Mayo Clinic.

For further information please download PDF attached:
Download this document